141 related articles for article (PubMed ID: 35090251)
1. [The prognostic relationship between CD56 expression and newly diagnosed multiple myeloma].
Geng CY; Yang GZ; Wang HJ; Zhou HX; Zhang ZY; Jian Y; Chen WM
Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):164-171. PubMed ID: 35090251
[No Abstract] [Full Text] [Related]
2. [Prognostic Value of CD56 Expression in Newly Diagnosed Multiple Myeloma Patients and Its Related Factors].
Wang XX; Zhang LL; Wang T; Hou JX; Wang ZT; Qin H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):777-782. PubMed ID: 37356939
[TBL] [Abstract][Full Text] [Related]
3. Newly diagnosed multiple myeloma patients with CD56 expression benefit more from autologous stem cell transplantation.
Geng C; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Yang G; Chen W
BMC Cancer; 2022 Dec; 22(1):1349. PubMed ID: 36564753
[TBL] [Abstract][Full Text] [Related]
4. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of CD56 antigen in newly diagnosed multiple myeloma: A real-world retrospective study.
Li L; Li X; Shang A; Zhao Y; Jin L; Zhao M; Shen W
Medicine (Baltimore); 2022 Oct; 101(40):e30988. PubMed ID: 36221376
[TBL] [Abstract][Full Text] [Related]
6. Absence of both CD56 and CD117 expression on malignant plasma cells is related with a poor prognosis in patients with newly diagnosed multiple myeloma.
Pan Y; Wang H; Tao Q; Zhang C; Yang D; Qin H; Xiong S; Tao L; Wu F; Zhang J; Zhai Z
Leuk Res; 2016 Jan; 40():77-82. PubMed ID: 26597998
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of CD56 expression in patients with multiple myeloma: a meta-analysis.
Zhang L; Huang Y; Lin Y; Zhang A; Zou R; Xu H; Wang S
Hematology; 2022 Dec; 27(1):122-131. PubMed ID: 35068378
[TBL] [Abstract][Full Text] [Related]
8. The Prognostic Role of Prothrombin Time and Activated Partial Thromboplastin Time in Patients with Newly Diagnosed Multiple Myeloma.
Geng C; Yang G; Wang H; Zhang Z; Zhou H; Chen W
Biomed Res Int; 2021; 2021():6689457. PubMed ID: 34104651
[TBL] [Abstract][Full Text] [Related]
9. [Clinical characteristics and outcomes of patients newly diagnosed with multiple myeloma with extramedullary disease].
Wang J; Zhang LN; Shi QL; Qu XY; Chen LJ; Li JY; Zhang R
Zhonghua Xue Ye Xue Za Zhi; 2020 Oct; 41(10):822-828. PubMed ID: 33190439
[No Abstract] [Full Text] [Related]
10. [The prognostic significance of dynamic monitoring of minimal residual disease (MRD) status in patients with newly-diagnosed multiple myeloma].
Yang PY; Liu MM; Fan HQ; Yang YP; Han W; Yu XY; Yue TT; Su KJ; Guo Q; Gao SJ; Jin FY
Zhonghua Xue Ye Xue Za Zhi; 2019 Jul; 40(7):584-588. PubMed ID: 32397022
[No Abstract] [Full Text] [Related]
11. Prognostic value of t(4;14) translocation in newly diagnosed multiple myeloma patients in novel agent era.
Geng C; Yang G; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Chen W
Hematology; 2023 Dec; 28(1):2161222. PubMed ID: 36607148
[TBL] [Abstract][Full Text] [Related]
12. Low Barthel index score is a poor prognostic factor for newly diagnosed multiple myeloma patients.
Geng C; Yang G; Zhou H; Wang H; Li Y; Leng Y; Zhang Z; Jian Y; Chen W
Clin Exp Med; 2023 Oct; 23(6):2593-2600. PubMed ID: 36703087
[TBL] [Abstract][Full Text] [Related]
13. [Impact of minimal residual disease detection after treatment of multiple myeloma].
Szendrei T; Plander M; Szabó Z; Kereskai L; Kajtár B; Papp G; Iványi JL
Orv Hetil; 2019 Mar; 160(13):502-508. PubMed ID: 30907098
[TBL] [Abstract][Full Text] [Related]
14. [Autologous stem cell transplantation improve the survival of newly diagnosed multiple myeloma patients].
Geng CY; Yang GZ; Wang GR; Wang HJ; Zhou HX; Zhang ZY; Jian Y; Chen WM
Zhonghua Xue Ye Xue Za Zhi; 2021 May; 42(5):390-395. PubMed ID: 34218581
[No Abstract] [Full Text] [Related]
15. Myc rearrangement redefines the stratification of high-risk multiple myeloma.
Jin X; Li H; Zhang D; Liu S; Song Y; Zhang F; Li Z; Zhuang J
Cancer Med; 2024 Jun; 13(11):e7194. PubMed ID: 38845529
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of circulating plasma cells detected by flow cytometry in newly diagnosed multiple myeloma patients: a systematic review and meta-analysis.
Liu X; Wu F; Ye W; Deng J; Zhang M; Zhang C; Yu Q; Cao L; Gan S; Ma J
BMJ Open; 2024 Jan; 14(1):e071548. PubMed ID: 38216195
[TBL] [Abstract][Full Text] [Related]
17. Prognostic implications of synaptophysin, CD56, thyroid transcription factor-1, and Ki-67 in pulmonary high-grade neuroendocrine carcinomas.
He Y; Zhao L; Tang X; Jiang Q; Zhao X; Cao Y
Ann Diagn Pathol; 2024 Feb; 68():152239. PubMed ID: 38006863
[TBL] [Abstract][Full Text] [Related]
18. CD56 Expression Is an Important Prognostic Factor in Multiple Myeloma Even with Bortezomib Induction.
Skerget M; Skopec B; Zadnik V; Zontar D; Podgornik H; Rebersek K; Furlan T; Cernelc P
Acta Haematol; 2018; 139(4):228-234. PubMed ID: 29920491
[TBL] [Abstract][Full Text] [Related]
19. Prognostic nomogram incorporating cytokines for overall survival in patients with newly diagnosed multiple myeloma.
Cheng Q; Zhao F; Zhang B; Zhang Y; Cai L; Qiao B; Hu Y; Sun C
Int Immunopharmacol; 2021 Oct; 99():108016. PubMed ID: 34385029
[TBL] [Abstract][Full Text] [Related]
20. Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients.
Geng C; Yang G; Wang H; Wu Y; Leng Y; Zhou H; Zhang Z; Jian Y; Chen W
Leuk Lymphoma; 2021 Apr; 62(4):883-890. PubMed ID: 33275060
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
